Table 3.
Treatment received in children infected with SARS-CoV-2
| Nature of treatment (data available)a | Number (%) of children, received the treatment |
|---|---|
| Medications | |
| Antibiotics, other than azithromycin (N = 64) | 5 (7.8) |
| Azithromycin (N = 84) | 40 (47.6) |
| Respiratory support | |
| Oxygen (N = 131) | 11 (8.4) |
| Non-invasive ventilation (N = 69) | 2 (2.9) |
| HHHFNC (N = 68) | 3 (4.4) |
| Mechanical ventilation (N = 233) | 14 (6.0) |
| Vasoactive support | |
| Inotropes (N = 174) | 19 (10.9) |
| Immune modulators | |
| HCQ (N = 201) | 11 (5.5) |
| Remdesivir (N = 129) | 3 (2.3) |
| IVIG (N = 142) | 4 (2.8) |
| Steroids (N = 136) | 11 (8.1) |
HHHFNC, heated humidified high flow nasal cannula; HCQ, hydroxychloroquine.
a
In the first column, N indicates the number of children for which that particular data are available.